Corcept Therapeutics Incorporated Financials

Market Capitalization $6.53 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	49.44
Forward PE	35.59
Price to Sales TTM	$10.38
Price to Book MRQ	$10.21
Enterprise to Revenue	9.79
Enterprise to EBITDA	42.70

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	22.56%
Operating Margin	25.53%
Return on Assets TTM	13.00%
Return on Equity TTM	25.77%

Income Statement

Revenue TTM	$628,555,008
Revenue per Share TTM	$6.11
Quarterly Revenue Growth	47.70%
Gross Profit TTM	$618,752,000
EBITDA	$144,865,000
Net Income to Common TTM	$140,487,008
Diluted EPS TTM	$1.26
Quarterly Earnings Growth YoY	50.50%

Balance Sheet

Total Cash MRQ	$380,336,000
Total Cash per Share MRQ	$3.63
Total Debt MRQ	$
Total Debt to Equity MRQ	1.06
Current Ratio MRQ	3.70
Book Value per Share MRQ	$6.10

Cash Flow

Operating Cash Flow TTM	$144,654,000
Levered Free Cash Flow TTM	$140,114,752

CORT Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	104,775,000
Float Shares	85,659,961
Avg 10 Volume	852,780
Avg 30 Volume	None
Shares Short	15,958,163
Short Ratio	18.99
Short % of Shares	21.39%
% Held by Insiders	11.52%
% Held by Institutions	85.79%

Stock Price Summary

Beta	0.46
Fifty Two Week Low	$20.84
Fifty Two Week High	$62.98
Fifty Two Week Change	62.78%
Day 50 MA	$55.39
Day 200 MA	$39.90

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date